ESOMEPRAZOLE IV MYLAN esomeprazole 40 mg (as sodium) powder for injection vial

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

esomeprazole sodium, Quantity: 42.5 mg (Equivalent: esomeprazole, Qty 40 mg)

Disponibbli minn:

MedTAS Pty Ltd

Għamla farmaċewtika:

Injection, powder for

Kompożizzjoni:

Excipient Ingredients: disodium edetate; sodium hydroxide; nitrogen

Rotta amministrattiva:

Intravenous Bolus, Intravenous Infusion

Unitajiet fil-pakkett:

10 vials

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

The short-term management of Gastro-Oesophageal Reflux Disease (GORD) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate.,Prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers.,Short-term management in patients requiring continued non-steroidal anti-inflammatory drug (NSAID) therapy when oral therapy is inappropriate:,? healing of gastric ulcers associated with NSAID therapy ? prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk,Esomeprazole IV MYLAN should be replaced with oral therapy as soon as practicable.

Sommarju tal-prodott:

Visual Identification: Esomeprazole 40 mg powder for injection is a white to off-white lyophilized porous cake or powder.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2022-01-14